WARNING Hepatotoxicity – Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product.
Hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain.
Dosage should be adjusted according to the severity of the pain and the response of the patient. However, it should be kept in mind that tolerance to hydrocodone can develop with continued use and that the incidence of untoward effects is dose related. The usual adult dosage for Hydrocodone Bitartrate and Acetaminophen Tablets USP is: Product Strength Usual Adult Dosage as needed for pain The total 24-hour dosage ...
| 5 mg/325 mg | 5 mg/500 mg | |||
| 7.5 mg/325 mg | 7.5 mg/500 mg | 7.5 mg/650 mg | 7.5 mg/750 mg | |
| 10 mg/325 mg | 10 mg/500 mg | 10 mg/650 mg | 10 mg/660 mg | 10 mg/750 mg |
Rx only
WARNING
Hepatotoxicity – Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product.
Hydrocodone Bitartrate and Acetaminophen Tablets are supplied in tablet form for oral administration.
Hydrocodone bitartrate is an opioid analgesic and antitussive and occurs as fine, white crystals or as a crystalline powder. It is affected by light. The chemical name is: 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5). It has the following structural formula:
Acetaminophen, 4'-hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:
Each Hydrocodone Bitartrate and Acetaminophen Tablet USP contains:
| Tablet | Hydrocodone Bitartrate USP | Acetaminophen USP |
| 5 mg/325 mg | 5 mg | 325 mg |
| 5 mg/500 mg | 5 mg | 500 mg |
| 7.5 mg/325 mg | 7.5 mg | 325 mg |
| 7.5 mg/500 mg | 7.5 mg | 500 mg |
| 7.5 mg/650 mg | 7.5 mg | 650 mg |
| 7.5 mg/750 mg | 7.5 mg | 750 mg |
| 10 mg/325 mg | 10 mg | 325 mg |
| 10 mg/500 mg | 10 mg | 500 mg |
| 10 mg/650 mg | 10 mg | 650 mg |
| 10 mg/660 mg | 10 mg | 660 mg |
| 10 mg/750 mg | 10 mg | 750 mg |
In addition each tablet contains the following inactive ingredients: crospovidone, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, silicon dioxide, and stearic acid.
The 10 mg/650 mg tablet also contains FD & C Blue No. 1 Aluminum Lake 12%.
Meets USP Dissolution Test 1.
Hydrocodone is a semisynthetic narcotic analgesic and antitussive with multiple actions qualitatively similar to those of codeine. Most of these involve the central nervous system and smooth muscle. The precise mechanism of action of hydrocodone and other opiates is not known, although it is believed to relate to the existence of opiate receptors in the central nervous system. In addition to analgesia, narcotics may produce drowsiness, changes in mood and mental clouding.
The analgesic action of acetaminophen involves peripheral influences, but the specific mechanism is as yet undetermined. Antipyretic activity is mediated through hypothalamic heat regulating centers. Acetaminophen inhibits prostaglandin synthetase. Therapeutic doses of acetaminophen have negligible effects on the cardiovascular or respiratory systems; however, toxic doses may cause circulatory failure and rapid, shallow breathing.
Pharmacokinetics – The behavior of the individual components is described below.
Hydrocodone – Following a 10 mg oral dose of hydrocodone administered to five adult male subjects, the mean peak concentration was 23.6 ± 5.2 ng/mL. Maximum serum levels were achieved at 1.3 ± 0.3 hours and the half-life was determined to be 3.8 ± 0.3 hours. Hydrocodone exhibits a complex pattern of metabolism including O-demethylation, N-demethylation and 6-keto reduction to the corresponding 6-α- and 6-β-hydroxy-metabolites (see OVERDOSAGE for toxicity information).
Acetaminophen – Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by liver damage and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug (see OVERDOSAGE for toxicity information).
Hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain.
This product should not be administered to patients who have previously exhibited hypersensitivity to hydrocodone or acetaminophen.
Patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to hydrocodone.
Hepatotoxicity – Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophen-containing products.
The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.
Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4000 milligrams of acetaminophen per day, even if they feel well.
Hypersensitivity/anaphylaxis – There have been post-marketing reports of hypersensitivity and anaphylaxis associated with use of acetaminophen. Clinical signs included swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergency medical attention. Instruct patients to discontinue Hydrocodone Bitartrate and Acetaminophen Tablets USP immediately and seek medical care if they experience these symptoms. Do not prescribe Hydrocodone Bitartrate and Acetaminophen Tablets USP for patients with acetaminophen allergy.
Respiratory Depression – At high doses or in sensitive patients, hydrocodone may produce dose-related respiratory depression by acting directly on the brain stem respiratory center. Hydrocodone also affects the center that controls respiratory rhythm, and may produce irregular and periodic breathing.
Head Injury and Increased Intracranial Pressure – The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a preexisting increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.
Acute Abdominal Conditions – The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.
Misuse, Abuse, and Diversion of Opioids – Hydrocodone bitartrate and acetaminophen tablets contains hydrocodone an opioid agonist, and is a Schedule III controlled substance. Opioid agonists have the potential for being abused and are sought by abusers and people with addiction disorders, and are subject to diversion.
Hydrocodone bitartrate and acetaminophen tablets can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing hydrocodone bitartrate and acetaminophen tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion (see DRUG ABUSE AND DEPENDENCE).
Special Risk Patients – As with any narcotic analgesic agent, hydrocodone bitartrate and acetaminophen tablets should be used with caution in elderly or debilitated patients and those with severe impairment of hepatic or renal function, hypothyroidism, Addison's disease, prostatic hypertrophy or urethral stricture. The usual precautions should be observed and the possibility of respiratory depression should be kept in mind.
Cough Reflex – Hydrocodone suppresses the cough reflex; as with all narcotics, caution should be exercised when hydrocodone bitartrate and acetaminophen tablets are used postoperatively and in patients with pulmonary disease.
Information for Patients/Caregivers
Hydrocodone, like all narcotics, may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery; patients should be cautioned accordingly.
Alcohol and other CNS depressants may produce an additive CNS depression, when taken with this combination product, and should be avoided.
Hydrocodone may be habit forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.
Laboratory Tests – In patients with severe hepatic or renal disease, effects of therapy should be monitored with serial liver and/or renal function tests.
Drug Interactions – Patients receiving other narcotic analgesics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone bitartrate and acetaminophen tablets may exhibit an additive CNS depression. When combined therapy is contemplated, the dose of one or both agents should be reduced.
The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
Drug/Laboratory Test Interactions – Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.
Carcinogenesis, Mutagenesis, Impairment of Fertility – No adequate studies have been conducted in animals to determine whether hydrocodone or acetaminophen have a potential for carcinogenesis, mutagenesis, or impairment of fertility.
Teratogenic Effects. Pregnancy Category C – There are no adequate and well-controlled studies in pregnant women. Hydrocodone bitartrate and acetaminophen tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nonteratogenic Effects – Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal.
Labor and Delivery – As with all narcotics, administration of this product to the mother shortly before delivery may result in some degree of respiratory depression in the newborn, especially if higher doses are used.
Nursing Mothers – Acetaminophen is excreted in breast milk in small amounts, but the significance of its effects on nursing infants is not known. It is not known whether hydrocodone is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocodone and acetaminophen, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use – Safety and effectiveness in the pediatric population have not been established.
Geriatric Use – Clinical studies of hydrocodone bitartrate and acetaminophen tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Hydrocodone and the major metabolites of acetaminophen are known to be substantially excreted by the kidney. Thus the risk of toxic reactions may be greater in patients with impaired renal function due to accumulation of the parent compound and/or metabolites in the plasma. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Hydrocodone may cause confusion and over-sedation in the elderly; elderly patients generally should be started on low doses of hydrocodone bitartrate and acetaminophen tablets and observed closely.
The most frequently reported adverse reactions include: lightheadedness, dizziness, sedation, nausea and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients and some of these adverse reactions may be alleviated if the patient lies down.
Other adverse reactions include:
Central Nervous System – Drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, psychic dependence, mood changes.
Gastrointestinal System – Prolonged administration of hydrocodone bitartrate and acetaminophen tablets may produce constipation.
Genitourinary System – Ureteral spasm, spasm of vesical sphincters and urinary retention have been reported with opiates.
Respiratory Depression – Hydrocodone bitartrate may produce dose-related respiratory depression by acting directly on the brain stem respiratory center (see OVERDOSAGE).
Special Senses – Cases of hearing impairment or permanent loss have been reported predominantly in patients with chronic overdose.
Dermatological – Skin rash, pruritus.
The following adverse drug events may be borne in mind as potential effects of acetaminophen: allergic reactions, rash, thrombocytopenia, agranulocytosis.
Potential effects of high dosage are listed in the OVERDOSAGE section.
Misuse, Abuse, and Diversion of Opioids – Hydrocodone bitartrate and acetaminophen tablets contains hydrocodone, an opioid agonist, and is a Schedule III controlled substance. Hydrocodone bitartrate and acetaminophen tablets, and other opioids used in analgesia can be abused and are subject to criminal diversion.
Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease utilizing a multidisciplinary approach, but relapse is common.
“Drug seeking” behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping” to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.
Abuse and addiction are separate and distinct from physical dependence and tolerance. Physical dependence usually assumes clinically significant dimensions only after several weeks of continued opioid use, although a mild degree of physical dependence may develop after a few days of opioid therapy. Tolerance, in which increasingly large doses are required in order to produce the same degree of analgesia, is manifested initially by a shortened duration of analgesic effect, and subsequently by decreases in the intensity of analgesia. The rate of development of tolerance varies among patients. Physicians should be aware that abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Hydrocodone bitartrate and acetaminophen tablets, like other opioids, may be diverted for non-medical use. Record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.
Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.
Following an acute overdosage, toxicity may result from hydrocodone or acetaminophen.
Hydrocodone – Serious overdose with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur.
Acetaminophen – In acetaminophen overdosage: dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. Renal tubular necrosis, hypoglycemic coma, and coagulation defects may also occur.
Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.
Treatment – A single or multiple drug overdose with hydrocodone and acetaminophen is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended.
Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered.
For hydrocodone overdose, primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote against respiratory depression which may result from overdosage or unusual sensitivity to narcotics, including hydrocodone. Since the duration of action of hydrocodone may exceed that of the antagonist, the patient should be kept under continued surveillance, and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression.
Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving liver injury is suspected. Intravenous NAC may be administered when circumstances preclude oral administration.
Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication.
Dosage should be adjusted according to the severity of the pain and the response of the patient. However, it should be kept in mind that tolerance to hydrocodone can develop with continued use and that the incidence of untoward effects is dose related.
The usual adult dosage for Hydrocodone Bitartrate and Acetaminophen Tablets USP is:
Product Strength | Usual Adult Dosage as needed for pain | The total 24-hour dosage should not exceed |
| 5 mg/325 mg | One to two tablets every four to six hours | 12 tablets |
| 5 mg/500 mg | One to two tablets every four to six hours | 8 tablets |
| 7.5 mg/325 mg | One tablet every four to six hours | 8 tablets |
| 7.5 mg/500 mg | One tablet every four to six hours | 6 tablets |
| 7.5 mg/650 mg | One tablet every four to six hours | 6 tablets |
| 7.5 mg/750 mg | One tablet every four to six hours | 5 tablets |
| 10 mg/325 mg | One tablet every four to six hours | 6 tablets |
| 10 mg/500 mg | One tablet every four to six hours | 6 tablets |
| 10 mg/650 mg | One tablet every four to six hours | 6 tablets |
| 10 mg/660 mg | One tablet every four to six hours | 6 tablets |
| 10 mg/750 mg | One tablet every four to six hours | 5 tablets |
Hydrocodone Bitartrate and Acetaminophen Tablets USP are supplied as follows:
| Strength | How Supplied | Each tablet contains: | Description of tablet | |
| Hydrocodone Bitartrate | Acetaminophen | |||
| 5 mg/325 mg | Bottles of 100 ……… NDC 0406-0365-01 Bottles of 500 ……… NDC 0406-0365-05 Unit Dose (10 x 10) … NDC 0406-0365-62 | 5 mg | 325 mg | It is available as a capsule-shaped white tablet debossed with M365 on one side and bisected on the other side. |
| 5 mg/500 mg | Bottles of 90 ….……NDC 0406-0357-09 Bottles of 100 ….……NDC 0406-0357-01 Bottles of 500 …….…NDC 0406-0357-05 Unit Dose (10 x 10) .….NDC 0406-0357-62 | 5 mg | 500 mg | It is available as a capsule-shaped white tablet debossed with M357 on one side and bisected on the other side. |
| 7.5 mg/325 mg | Bottles of 100 …….…NDC 0406-0366-01 Bottles of 500 …….…NDC 0406-0366-05 Unit Dose (10 x 10) ….NDC 0406-0366-62 | 7.5 mg | 325 mg | It is available as an unscored oval-shaped white tablet debossed with M366 on one side. |
| 7.5 mg/500 mg | Bottles of 100 …….…NDC 0406-0358-01 Bottles of 500 …….…NDC 0406-0358-05 Unit Dose (10 x 10) …..NDC 0406-0358-62 | 7.5 mg | 500 mg | It is available as a capsule-shaped white tablet debossed with M358 on one side and bisected on the other side. |
| 7.5 mg/650 mg | Bottles of 100 ……… NDC 0406-0359-01 Bottles of 500 ……… NDC 0406-0359-05 | 7.5 mg | 650 mg | It is available as a capsule-shaped white tablet debossed with M359 on one side and bisected on the other side. |
| 7.5 mg/750 mg | Bottles of 90 ….……NDC 0406-0360-09 Bottles of 100 ……… NDC 0406-0360-01 Bottles of 500 ……… NDC 0406-0360-05 | 7.5 mg | 750 mg | It is available as a capsule-shaped white tablet debossed with M360 on one side and bisected on the other side. |
| 10 mg/325 mg | Bottles of 100 …….… NDC 0406-0367-01 Bottles of 500 ….…… NDC 0406-0367-05 Unit Dose (10 x 10) ….. NDC 0406-0367-62 | 10 mg | 325 mg | It is available as a capsule-shaped white tablet debossed with M367 on one side and bisected on the other side. |
| 10 mg/500 mg | Bottles of 100 …….… NDC 0406-0363-01 Bottles of 500 ……… NDC 0406-0363-05 Unit Dose (10 x 10) …. NDC 0406-0363-62 | 10 mg | 500 mg | It is available as a capsule-shaped white tablet debossed with M363 on one side and bisected on the other side. |
| 10 mg/650 mg | Bottles of 100 ……..…NDC 0406-0361-01 Bottles of 500 …….… NDC 0406-0361-05 Unit Dose (10 x 10). ….NDC 0406-0361-62 | 10 mg | 650 mg | It is available as a capsule-shaped blue tablet debossed with M361 on one side and bisected on the other side. |
| 10 mg/660 mg | Bottles of 100 ………. NDC 0406-0362-01 | 10 mg | 660 mg | It is available as a capsule-shaped white tablet debossed with M362 on one side and bisected on the other side. |
| 10 mg/750 mg | Bottles of 100 ………. NDC 0406-0364-01 | 10 mg | 750 mg | It is available as a capsule-shaped white tablet debossed with M364 on one side and bisected on the other side. |
Dispense in a tight, light-resistant container (as defined in USP) with a child-resistant closure.
Storage – Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.
A Schedule III controlled drug substance.
Mallinckrodt Inc.
Hazelwood, MO 63042 USA
Mallinckrodt
COVIDIEN™
Printed in U.S.A.
Rev 05/2011
Repackaged by:
Contract Pharmacy Services-PA
125 Titus Ave Suite 200
Warrington, PA 18976 USA
Original--1/2012--NJW
| Class | Version | Type | Effective |
|---|---|---|---|
| HYDROCODONE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 67046-926-30 | 2019-11-13 | C162847 | 48780-1 | 97449f38-c698-f6ea-e053-dbdaa90aa703 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS USP CIII |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 67046-926-30 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | 30 in 1 BLISTER PACK | TABLET | 30 | 1 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0406-0357-01 | EA - Each | 0406-0357 | 5e99876e-18d3-4aab-bb1f-a29985e52f67 | 1 | 2012-07-24 |
| 0406-0357-05 | EA - Each | 0406-0357 | cf68f85b-0a2e-4c78-b3c5-784d4f5d751d | 1 | 2012-07-24 |
| 0406-0357-09 | EA - Each | 0406-0357 | 06374d9c-9f07-4a1a-9388-c722618ccd1b | 1 | 2012-07-24 |
| 0406-0357-23 | EA - Each | 0406-0357 | ed749a1a-614e-44a2-b052-4e92c16e8a8d | 1 | 2013-03-03 |
| 0406-0357-62 | EA - Each | 0406-0357 | a2a0c72b-664a-4de5-a43e-c3235fb5c80e | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ACETAMINOPHEN | ACTIVE INGREDIENT | 362O9ITL9D | 1 | |
| HYDROCODONE BITARTRATE | ACTIVE INGREDIENT | NO70W886KK | 1 | |
| ACETAMINOPHEN | ACTIVE MOIETY | 362O9ITL9D | 1 | |
| HYDROCODONE | ACTIVE MOIETY | 6YKS4Y3WQ7 | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 1 | |
| CROSPOVIDONE | INACTIVE INGREDIENT | 68401960MK | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| POVIDONE | INACTIVE INGREDIENT | FZ989GH94E | 1 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| STARCH, CORN | INACTIVE INGREDIENT | O8232NY3SJ | 1 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 67046-926 | 67046-926-30 |
| 0406-0357 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| HYDROCODONE BITARTRATE | NO70W886KK | ACTIB |
| CROSPOVIDONE | 68401960MK | IACT |
| ACETAMINOPHEN | 362O9ITL9D | ACTIB |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| CELLULOSE, MICROCRYSTALLINE | OP1R32D61U | IACT |
| POVIDONE | FZ989GH94E | IACT |
| STARCH, CORN | O8232NY3SJ | IACT |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| STEARIC ACID | 4ELV7Z65AP | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 170 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, ORALLY DISINTEGRATING / ORAL | 10 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | SUSPENSION, EXTENDED RELEASE / ORAL | 113 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | POWDER, FOR SUSPENSION / ORAL | 1203 mg/5ml | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET / ORAL | 336 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET / SUBLINGUAL | 6 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | INSERT / VAGINAL | 69 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TROCHE / ORAL | 300 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | SUSPENSION/ DROPS / ORAL | 90 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | DROPS / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SUSPENSION / ORAL | 2553 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE / ORAL | 5000 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | DROPS / ORAL | NA | ||
| POVIDONE | POVIDONE | FZ989GH94E | SUSPENSION/ DROPS / OPHTHALMIC | 0.6 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SYSTEM / TRANSDERMAL | 35 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | SUSPENSION / AURICULAR (OTIC) | NA | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / BUCCAL | 18 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | INSERT / VAGINAL | 8 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | SUSPENSION / ORAL | 1600 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | SYSTEM / TOPICAL | 41 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | OINTMENT / TOPICAL | 15 %w/w | ||
| POVIDONE | POVIDONE | FZ989GH94E | CAPSULE, COATED PELLETS / ORAL | 10.03 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, COATED PELLETS / ORAL | 456 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | SUSPENSION / ORAL | 20 mg/5ml | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, DELAYED RELEASE / ORAL | 144 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE, FOR SUSPENSION / ORAL | 14 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / VAGINAL | 8 %w/w | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET / ORAL | 1116 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED / ORAL | 3 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / RESPIRATORY (INHALATION) | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PELLET / ORAL | 34 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | RING / VAGINAL | 2 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, EXTENDED RELEASE / ORAL | 168 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, EXTENDED RELEASE / ORAL | 1246 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION / ORAL | 64 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET / BUCCAL | 16.6 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PASTE / DENTAL | 34 %w/w | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, ORALLY DISINTEGRATING / ORAL | 1800 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, EXTENDED RELEASE / ORAL | 450 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET, FOR SUSPENSION / ORAL | 2 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | PELLET / ORAL | 24 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, LIQUID FILLED / ORAL | 106 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 19 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / SUBLINGUAL | 17.5 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / SUBCUTANEOUS | 0.5 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION, EXTENDED RELEASE / ORAL | 71 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / TRANSMUCOSAL | 100 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | EMULSION / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE / ORAL | 1190 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, DELAYED RELEASE / ORAL | 2210 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A089160-001 | ANEXSIA | ACETAMINOPHEN; HYDROCODONE BITARTRATE | 500MG;5MG | TABLET / ORAL | 1987-04-23 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A089160-001 | ANEXSIA | 500MG;5MG | TABLET / ORAL | 1987-04-23 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ab6b4c39-b2d4-4c63-8821-b0560f781287 | ab6b4c39-b2d4-4c63-8821-b0560f781287 | 2012-01-23 | Boxed warning, Warnings, Adverse reactions | ab6b4c39-b2d4-4c63-8821-b0560f781287 ab6b4c39-b2d4-4c63-8821-b0560f781287 |
Adverse event summaries are temporarily unavailable. Other product information remains available.